Leqvio FDA Approval

Agenda Introduction Samir Shah, Global Head of Investor Relations Overview Marie-France Tschudin, President of Novartis Pharmaceuticals LeqvioⓇ clinical data and label David Soergel, MD, Head of Global Drug Development Cardio Renal Metabolism US market and launch readiness Victor Bulto, Head of Novartis Pharma US Q&A Samir Shah, Global Head of Investor Relations 3 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation NOVARTIS | Reimagining Medicine

View entire presentation